Cancer
Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
Published in Drug Week, May 4th, 2007
Kosan Biosciences Incorporated (NASDAQ:KOSN) today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and in vivo cancer models. KOS-1803 has been chemically engineered to have a favorable tissue distribution pattern, which has been shown in models to result in excellent tumor penetration and a low side effect profile. In human tumor xenograft models, KOS-1803 has demonstrated antitumor activity in breast, lung, prostate and colorectal cancers, as well as in ovarian cancer and neuroblastoma where the extent and duration of tumor regression was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-05-04)
More Articles from Drug Week
- Acute Lymphoblastic Leukemia
Progress toward a targeted therapy for a specific form of leukemia - Addiction Medicine
Brief physician interventions have impact on problem drinking - Addiction Medicine
UCSF launches study on treatment for prescription drug addiction - Alzheimer Disease
Research could lead to treatment for Alzheimer's disease - Amyotrophic Lateral Sclerosis
Diseased Brain Cells Involved In ALS Motor Neuron Death - Anemia
Study produces conflicting findings on the use of anti-anemia drug in cancer patients - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
